Biotechs are blowing up -- and ISIS Pharmaceuticals (ISIS) is showing an attractive buy right now with potential 12% upside. More
-
-
Sponsored By:
-
Sponsored By:
XBI
Recent Articles
Bull’s Eye Report: Pharmacyclics (PCYC)
Pharmacyclics (PCYC) is our top pick today as an outperformer in the biotech space. More
Bull’s Eye Report: Pharmacyclics (PCYC)
Biotech is a hot industry that's extremely volatile right now. Get on the right side of that volatility with Pharmacyclics (PCYC). More
Bull’s Eye Report: United Therapeutics Group (UTHR)
United Therapeutics (UTHR) should move back up to recent highs around $63, and today presents a great opportunity to get in. More
Make a Straightforward Play in Biotech
The iShares Nasdaq Biotechology Index Fund is a great way to get into biotechs ... just not now. It's due for a buyers' exhaustion break, so wait and keep watch. More
Bull’s Eye Report: Regeneron Pharmaceuticals (REGN)
Looking for a non-correlated asset to beat the market in a potential downturn? Look no further than biotech stock Regeneron Pharmaceuticals (REGN). More
Bull’s Eye Report: Regeneron Pharmaceuticals (REGN)
REGN gained 208.65% on the year in 2012, and while normally this would indicate a parabolic run, the short-term prospects for a trade still look pretty good. More
